Preclinical studies with morpholino antisense oligonucleotides (ASO) showed that a single injection increased SMN protein levels in both SMA and heterozygote mice, but not to the levels of control animals (73). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.